SRPT – YEAR 4 DATA ANALYSIS

  YEAR 4 DATA ANALYSIS Review of Eteplirsen to treat DMD By: @boscaptn, et al.   Compiled From SAREPTA Public Data For Week 216 (Year 4) of Study 201/202 for Exon 51   Disclaimer: NO FINANCIAL ADVICE – The Information in this report is provided for education and informational purposes only, without any express or […]

March 7 Biotech Update

I hope everyone had a good weekend. We are off to a rather slow start with not a lot of meaningful news (again). We have a more positive sentiment background and likely the continued short covering rally, so that might be enough to move the sector higher. The trend that I want to watch this […]

March 4 Biotech Update

I am more confident in my recent speculation that we have been seeing short covering in the SMID and cash raising through the selling of large caps. ISI had a note this morning that noted something similar about the large caps where 4 of the 10 largest laggards in the S&P yesterday were biotech. He […]

Dave-Trading BIIB

  *** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** Before we get to the meat of the trade, I want to address a recent question. How do I know how much capital to […]

March 3 Biotech Update

We are actually seeing something interesting in the sector where small caps are outperforming large caps (by a wide margin). Are investors finally starting to get more comfortable and increasing their risk? Could certainly be the case but it also is consistent with the short covering rally thesis. Just about all of the SMID biotech […]

March 2 Biotech Update

The market has a good rally off of the lows yesterday and despite still feeling concerned about the market it has actually had a nice rally in the second half of February. The problem is that two weeks of good price action is not nearly enough to get rid of the damage especially in the […]

February 29 Biotech Update

I would have expected more action to start the week but it has been pretty quiet. It looks like we are left to the sentiment tides once again as there is nothing I see on the news front that can make a dent in either direction. As such, I will spend today mainly talking about […]

February 26 Biotech Update

I was supposed to be back from travelling yesterday but the weather cancelled my flight but I am back at it today. Of course, I did not miss a lot of bullish action although there has been some SMID earnings that I want to touch on. We seem to be back in the pattern that […]

Buy DeLo, Sell DeHigh – RUT

  *** Jason DeLorenzo is an income options trader. He trades on indexes mostly, but will trade positions based on CRG theses*** On 2/18 close to the market close, Joe tweeted this: “Joe ‏@GantosJ Feb 18: The “Three Gaps Up” pattern $SPY $IBB $XBI is only a warning that exhaustion in the way, BUT expanding […]

February 22 Biotech Update

It is a good start to the week as the markets open green and everything seems to be heading higher. One could argue that the trend of selling the rallies has broken but I still think we need to decisively put in a higher low and higher high before we can get any confidence in […]

February 19 Biotech Update

We are getting the pullback after that quick rip your face off rally and so now is the real moment of truth. Did the rally simply reset the relative strength to allow another leg lower or will buyers step in and buy this pullback? As I noted before there is no way of knowing and […]

Dave-Trading – GILD

Gilead – GILD *** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** Dave LOVES writing about GILD.  Their combined Hep C franchise is by all metrics the most successful launch ever, so it is […]

February 18 Biotech Update

We continue to have a short covering rally as the most shorted stocks continue to outperform. This seems to be the mantra of people who want to discount the move but as I said before there is no reason to suspect that the bounce off the lows would be anything but a short covering rally. […]

February 17 Biotech Update

We are having a green opening after back to back green days, which is pretty rare this year. We have obviously been due for a bounce and whether this is the bottom or a dead cat bounce is yet to be determined. This move is driven by short covering (the most shorted stocks are greatly […]

February 12 Biotech Update

The market remains crazy and the sector is filled with odd moves. Yesterday seemed to be a good day of outperformance for the large caps and today they are red while the market is green. There were some good movers in SMID yesterday and today but not a real rhyme or reason for who outperforms […]

February 11 Biotech Update

The markets remain in turmoil despite a nice start (but poor finish) yesterday. Interestingly it seemed yesterday at least that large cap biotech outperformed the broader market. Obviously it could very easily be an oversold bounce but in a world of limited earnings growth, one could make the case that some of the large cap […]

February 10 Biotech Update

I am glad I was out of the office for the start of the week as the market took a drubbing. While today is certainly starting off better, this is still not a healthy market. I want to spend some time talking macro and then broadly about biotech and end with some specific company news. […]

Options Basics (4) – Options Strategies

  So far, we discussed all the essential option characteristics. What an option is, its variables, and how to use options for risk adjustment. So now that you know these things, there are several “goto” strategies that take advantage of the flexibility of options. These are general strategies, and not specific to a trade. When […]